Literature DB >> 20219330

Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.

Enrico Tedeschini1, Maurizio Fava, Tracie M Goodness, George I Papakostas.   

Abstract

An increased likelihood of receiving placebo in randomized clinical trials has been found to predict greater chances of trial success. However, patients who are less likely to receive active therapy (and more likely to receive placebo) may be at increased risk of attrition which, in turn, can limit the statistical power of a study. Therefore, in the present work, we sought to investigate the relationship between the probability of receiving placebo and the likelihood of prematurely discontinuing treatment. Medline/Pubmed publication databases were searched for RCT in MDD. A meta-regression established that the likelihood of receiving placebo did not predict either antidepressant discontinuation rates, placebo-discontinuation rates or the risk ratio of discontinuing antidepressants versus placebo. An increased likelihood of receiving placebo did not inflate discontinuation rates which did not influence the degree of antidepressant-placebo "separation". Copyright 2010 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219330     DOI: 10.1016/j.euroneuro.2010.02.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

1.  The role of regulators, investigators, and patient participants in the rise of the placebo response in major depressive disorder.

Authors:  Maurizio Fava
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

2.  Randomization to randomization probability: Estimating treatment effects under actual conditions of use.

Authors:  Brandon J George; Peng Li; Harris R Lieberman; Greg Pavela; Andrew W Brown; Kevin R Fontaine; Madeline M Jeansonne; Gareth R Dutton; Adeniyi J Idigo; Mariel A Parman; Donald B Rubin; David B Allison
Journal:  Psychol Methods       Date:  2017-04-13

3.  Improving study design for antidepressant effectiveness assessment.

Authors:  Florian Naudet; Bruno Millet; Jean Michel Reymann; Bruno Falissard
Journal:  Int J Methods Psychiatr Res       Date:  2013-08-30       Impact factor: 4.035

Review 4.  The placebo response in medicine: minimize, maximize or personalize?

Authors:  Paul Enck; Ulrike Bingel; Manfred Schedlowski; Winfried Rief
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 5.  Mechanisms of the placebo effect in pain and psychiatric disorders.

Authors:  R D Holmes; A K Tiwari; J L Kennedy
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.